Compare FCF & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCF | NVCR |
|---|---|---|
| Founded | 1934 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 1994 | 2015 |
| Metric | FCF | NVCR |
|---|---|---|
| Price | $20.94 | $15.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $19.75 | ★ $28.08 |
| AVG Volume (30 Days) | 806.8K | ★ 922.2K |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | 5.76 | ★ 21.79 |
| EPS | ★ 0.81 | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $16.32 | $7.72 |
| Revenue Next Year | $6.25 | $6.74 |
| P/E Ratio | $25.85 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $15.00 | $9.82 |
| 52 Week High | $22.34 | $21.45 |
| Indicator | FCF | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 48.98 | 42.57 |
| Support Level | $20.45 | $14.93 |
| Resistance Level | $21.52 | $18.43 |
| Average True Range (ATR) | 0.34 | 0.70 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 38.73 | 30.84 |
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.